Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Antibody-drug conjugate (CD19/PBD)
Loncastuximab tesirine
Zynlonta · LON
CD19-directed pyrrolobenzodiazepine ADC whose capillary-leak-type edema, effusions and fluid overload are the renal-relevant signals in DLBCL.
ModeratePyrrolobenzodiazepine ADC era · approved 2021
Relapsed/refractory large B-cell lymphoma (DLBCL not otherwise specified, high-grade B-cell lymphoma) after >=2 systemic therapies
Signature kidney injury
Prerenal / Hemodynamic AKI
Edema and effusions (pleural, pericardial, peritoneal) are characteristic PBD-payload toxicities and were common in LOTIS-2; the resulting fluid shifts and AKI are not separately quantified. Tumor lysis is an additional consideration in responding lymphoma.
Source: Caimi et al., Lancet Oncol 2021 (LOTIS-2)
Mechanism of kidney injury
The PBD payload causes endothelial/vascular injury producing a capillary-leak-type syndrome with peripheral edema, serosal effusions and fluid extravasation. Intravascular volume depletion from third-spacing drives prerenal azotemia, while fluid overload can complicate management; severe capillary leak can cause hemodynamic AKI. The CD19 target is restricted to B cells, so the renal injury is payload-mediated and hemodynamic rather than a direct antibody-target nephrotoxicity. Tumor lysis can add crystalline injury in responders.
Clinical presentation
Progressive peripheral edema, weight gain, dyspnea from pleural/pericardial effusions and ascites; a prerenal creatinine rise from intravascular depletion despite total-body fluid excess. TLS labs may appear in responders.
Onset
Edema/effusions accumulate over cycles; prerenal changes track the fluid shifts.
Reversibility
Reversible
Anticancer mechanism
Antibody-drug conjugate of an anti-CD19 antibody linked to a pyrrolobenzodiazepine (PBD) dimer payload. After CD19 binding and internalization, the released PBD cross-links DNA, causing death of malignant B cells in diffuse large B-cell lymphoma.
Management
Manage edema/effusions with judicious diuresis (avoiding worsening prerenal physiology), drainage of symptomatic effusions, and dose modification/delay. Restore effective circulating volume for prerenal AKI. Treat tumor lysis with hydration, urate-lowering therapy and electrolyte correction. Renal effects generally improve as fluid shifts resolve.
Risk factors
- Pre-existing cardiac/renal dysfunction or hypoalbuminemia
- Higher cumulative ADC exposure
- High tumor burden (tumor-lysis risk)
- Concurrent nephrotoxins
Prevention
- Monitor weight, edema and effusions each cycle; premedicate (dexamethasone) per label to reduce fluid accumulation
- Assess volume status carefully before diuresis (third-spacing with intravascular depletion)
- Tumor-lysis risk assessment with hydration +/- urate-lowering therapy
- Dose delay/reduction for significant edema/effusions
Note · The renal link is indirect — payload-driven capillary-leak edema/effusions cause fluid shifts and prerenal AKI rather than a direct target nephrotoxicity; tumor lysis adds risk in responders.
Clinical depth
Renal dose adjustment
No dose adjustment for mild-moderate renal impairment; severe impairment/ESKD not well studied. As an ADC, clearance is not primarily renal.
Dialyzability & ESKD dosing
A large antibody-drug conjugate; not dialyzable. ESKD dosing is not established.
Differential diagnosis
Distinguish capillary-leak/effusion-related prerenal AKI (intravascular depletion despite edema) from cardiac failure, nephrotic-range proteinuria, and tumor-lysis nephropathy. Assess effective circulating volume before diuresing.
Monitoring
- Weight, edema and effusion assessment each cycle
- Serum creatinine, albumin and electrolytes
- TLS labs in responders (uric acid, phosphate, potassium)
- Liver tests and CBC per schedule
Key trials & series
- LOTIS-2 (Caimi, Lancet Oncol 2021) — registrational single-arm trial characterizing edema/effusion toxicity
Clinical pearls
- PBD-payload capillary leak causes total-body fluid excess with intravascular depletion — diurese cautiously.
- Edema and serosal effusions are the signature ADC toxicities to track each cycle.
- Premedication (dexamethasone) mitigates fluid accumulation.
- As an ADC it is not dialyzable; clearance is not renal.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of antibody-drug conjugate (cd19/pbd)s.
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression (payload-dependent)
Ophthalmic
Keratopathy, uveitis, retinopathy
- Keratopathy (belantamab, mirvetuximab, tisotumab)
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Interstitial lung disease (deruxtecan ADCs)
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Peripheral neuropathy (MMAE payloads)
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkLoncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Caimi PF et al. · Lancet Oncol 2021 · PMID 33989558Registrational trial characterizing the edema/effusion (capillary-leak-type) toxicity driving renal fluid shifts.PMIDLoncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from LOTIS-2.Caimi PF et al. · Haematologica 2024 · PMID 37646659Updated safety confirming the edema/effusion and fluid-overload pattern.PMIDLoncastuximab Tesirine: First Approval.Lee A et al. · Drugs 2021 · PMID 34143407Approval profile summarizing the PBD-ADC mechanism and toxicity.PMIDPyrrolobenzodiazepine antibody-drug conjugates: mechanism and toxicity.Corbett S et al. · Mol Cancer Ther 2020 · PMID 32669316Mechanistic basis of PBD-payload vascular/capillary-leak toxicity.PMIDLoncastuximab tesirine combinations and real-world outcomes in large B-cell lymphoma.Alderuccio JP et al. · Lancet Haematol 2024 · PMID 39662486Broader clinical experience contextualizing toxicity management.PMIDOnconephrology: The Intersections Between the Kidney and Cancer.Rosner MH et al. · CA Cancer J Clin 2021 · PMID 32998135Framework for capillary-leak/hemodynamic and tumor-lysis AKI.
Related agents
Other agents sharing the same signature kidney injury.